Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival
Jesse M. Tettero, Lok Lam Ngai, Costa Bachas, Dimitri Breems, Thomas Fischer, Bjørn Tore Gjertsen, Patrycja Gradowska, Laimonas Griškevičius, Jeroen J. W. M. Janssen, Gunnar Juliusson, Johan Maertens, Markus G. Manz, Thomas Pabst, Jakob Passweg, Kimmo Porkka, Peter J.M. Valk, Bob Löwenberg, Gert J. Ossenkoppele, Jacqueline Cloos
Abstract
Not available.
Topics & Concepts
Myeloid leukemiaMedicineMinimal residual diseaseTransplantationOncologyDiseaseInternal medicineLeukemiaImmunologyAcute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationAcute Lymphoblastic Leukemia research